drugset / Trial / NCT03450187
A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study
Phase 1
Completed
40 enrolled
Tetraphase Pharmaceuticals, Inc
National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedParallel-groupQuadruple-blindOther
Summary
This is a phase 1, single-center, randomized, placebo-controlled, double-blind, multiple ascending-dose study to assess the safety, tolerability, and PK of oral TP-271 in healthy adult subjects. Male or female subjects aged 18 to 50 years who fulfill the inclusion/exclusion criteria will be enrolled in this study.
Timeline
- Start
- 2018-03-20
- Primary completion
- 2018-12-31
- Completion
- 2019-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | TP-271 | Small molecule | 50 mg | Oral |
| Comparator | TP-271 | Small molecule | 100 mg | Oral |
| Comparator | TP-271 | Small molecule | 200 mg | Oral |
| Comparator | TP-271 | Small molecule | 300 mg | Oral |
| Comparator | TP-271 | Small molecule | 400 mg | Oral |